GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000915019 | Prostate | Tumor | purine ribonucleotide metabolic process | 109/3246 | 368/18723 | 3.30e-09 | 1.36e-07 | 109 |
GO:000925918 | Prostate | Tumor | ribonucleotide metabolic process | 110/3246 | 385/18723 | 2.45e-08 | 8.29e-07 | 110 |
GO:000616319 | Prostate | Tumor | purine nucleotide metabolic process | 111/3246 | 396/18723 | 6.46e-08 | 1.88e-06 | 111 |
GO:001969318 | Prostate | Tumor | ribose phosphate metabolic process | 111/3246 | 396/18723 | 6.46e-08 | 1.88e-06 | 111 |
GO:007252119 | Prostate | Tumor | purine-containing compound metabolic process | 115/3246 | 416/18723 | 8.47e-08 | 2.31e-06 | 115 |
GO:000915218 | Prostate | Tumor | purine ribonucleotide biosynthetic process | 53/3246 | 169/18723 | 5.62e-06 | 8.63e-05 | 53 |
GO:000926016 | Prostate | Tumor | ribonucleotide biosynthetic process | 54/3246 | 182/18723 | 2.71e-05 | 3.29e-04 | 54 |
GO:000911718 | Prostate | Tumor | nucleotide metabolic process | 120/3246 | 489/18723 | 2.81e-05 | 3.41e-04 | 120 |
GO:000675317 | Prostate | Tumor | nucleoside phosphate metabolic process | 121/3246 | 497/18723 | 3.81e-05 | 4.41e-04 | 121 |
GO:004639016 | Prostate | Tumor | ribose phosphate biosynthetic process | 55/3246 | 190/18723 | 4.89e-05 | 5.42e-04 | 55 |
GO:007252215 | Prostate | Tumor | purine-containing compound biosynthetic process | 55/3246 | 200/18723 | 2.16e-04 | 1.86e-03 | 55 |
GO:000616415 | Prostate | Tumor | purine nucleotide biosynthetic process | 53/3246 | 191/18723 | 2.18e-04 | 1.87e-03 | 53 |
GO:000916514 | Prostate | Tumor | nucleotide biosynthetic process | 61/3246 | 254/18723 | 4.03e-03 | 2.04e-02 | 61 |
GO:190129314 | Prostate | Tumor | nucleoside phosphate biosynthetic process | 61/3246 | 256/18723 | 4.84e-03 | 2.37e-02 | 61 |
GO:000912612 | Prostate | Tumor | purine nucleoside monophosphate metabolic process | 15/3246 | 44/18723 | 5.49e-03 | 2.61e-02 | 15 |
GO:00091676 | Prostate | Tumor | purine ribonucleoside monophosphate metabolic process | 14/3246 | 41/18723 | 7.07e-03 | 3.18e-02 | 14 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
AMPD1 | SNV | Missense_Mutation | novel | c.1001N>G | p.Asp334Gly | p.D334G | P23109 | protein_coding | deleterious(0) | probably_damaging(0.967) | TCGA-A2-A3XS-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | PD |
AMPD1 | SNV | Missense_Mutation | | c.679C>G | p.Pro227Ala | p.P227A | P23109 | protein_coding | deleterious(0.02) | probably_damaging(0.996) | TCGA-A8-A097-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
AMPD1 | SNV | Missense_Mutation | | c.1710G>T | p.Lys570Asn | p.K570N | P23109 | protein_coding | tolerated(0.23) | benign(0.021) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AMPD1 | SNV | Missense_Mutation | | c.2019N>T | p.Lys673Asn | p.K673N | P23109 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-AO-A0J4-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
AMPD1 | SNV | Missense_Mutation | novel | c.587C>T | p.Ser196Phe | p.S196F | P23109 | protein_coding | deleterious(0) | probably_damaging(0.95) | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
AMPD1 | SNV | Missense_Mutation | | c.558N>C | p.Lys186Asn | p.K186N | P23109 | protein_coding | tolerated(0.2) | benign(0.14) | TCGA-E2-A14Z-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | PD |
AMPD1 | SNV | Missense_Mutation | | c.1879C>G | p.His627Asp | p.H627D | P23109 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EW-A1PH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
AMPD1 | insertion | Frame_Shift_Ins | novel | c.1287_1288insCAAGCATGTAAGCATGACCCTTCAGGCCTTCATAC | p.Tyr430GlnfsTer26 | p.Y430Qfs*26 | P23109 | protein_coding | | | TCGA-AO-A0J9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD |
AMPD1 | SNV | Missense_Mutation | novel | c.1502N>T | p.Ser501Phe | p.S501F | P23109 | protein_coding | deleterious(0) | possibly_damaging(0.595) | TCGA-C5-A1BL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
AMPD1 | SNV | Missense_Mutation | novel | c.256N>A | p.Glu86Lys | p.E86K | P23109 | protein_coding | deleterious(0) | possibly_damaging(0.847) | TCGA-C5-A905-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |